{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:52:42Z","timestamp":1791175962530,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorders (NMOSD) are severe autoimmune diseases of the central nervous system characterized by autoantibodies against aquaporin 4 (AQP4-IgG). Despite the availability of several molecular targeted therapies, biomarkers capable of predicting subsequent disability early during the acute relapse phase remain insufficient. Given that abnormalities in immune checkpoint molecules are known to be involved in autoimmunity, this study investigated whether immune checkpoint-related molecules in the cerebrospinal fluid (CSF) of acute-phase AQP4-IgG-positive NMOSD patients correlate with disability at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-four patients with AQP4 IgG-positive NMOSD, 10 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)at disease flare, and 11 patients with idiopathic normal pressure hydrocephalus (iNPH) as control non-inflammatory neurological disease were enrolled. Bead-based multiplex assays were used to quantify levels of immune checkpoint molecules and related factors (PD-1, PD-L1, CTLA-4, TIM-3, galectin-9, LAG-3, 4-1BB, B7.2, IL-2R\u03b1, TGF-\u03b21, FasL) in CSF. These molecules were measured in the soluble fraction. Disease severity at 6 months was classified as mild (EDSS &amp;lt; 6) or severe (EDSS \u2265 6). ROC analysis was performed to evaluate prognostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six cases of NMOSD showed mild disability, and 8 cases showed severe disability. All cases of MOGAD showed mild disability. Compared to the mild group, the severe group had higher age, a higher male ratio, and higher cerebrospinal fluid protein levels (p=0.004, p=0.017, p&amp;lt;0.001, respectively). Cerebrospinal fluid levels of TIM-3, galectin-9, and IL-2R\u03b1 were significantly higher in the severe group (p=0.011, p=0.008, p=0.006, respectively), with area under the ROC curve values of 0.89, 0.88, and 0.80, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In AQP4-IgG-positive NMOSD patients, elevated levels of TIM-3, galectin-9, and IL-2R\u03b1 in CSF during the acute attack phase correlate with worsening disability severity at 6 months. These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1923404","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:33:07Z","timestamp":1791174787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder"],"prefix":"10.3389","volume":"17","author":[{"given":"Shota","family":"Nishii","sequence":"first","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsu","family":"Akatani","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoka","family":"Shiroma","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asato","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Katanazaka","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Koto","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Chihara","sequence":"additional","affiliation":[{"name":"Division of Neurology, Kobe University Graduate School of Medicine","place":["Kobe, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00776-4","article-title":"Origins and immunopathogenesis of autoimmune central nervous system disorders","volume":"19","author":"Ramanathan","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51964","article-title":"Association of plasma sPD-1 and sPD-L1 with disease status and future relapse in AQP4-IgG (+) NMOSD","volume":"11","author":"Liu","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578289","article-title":"Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD","volume":"388","author":"Haham","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2176\/nmc.st.2020-0292","article-title":"Guidelines for management of idiopathic normal pressure hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus","volume":"61","author":"Nakajima","year":"2021","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00415-026-13791-4","article-title":"Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma","volume":"273","author":"Nishii","year":"2026","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2019.06.001","article-title":"LEGENDplex: Bead-assisted multiplex cytokine profiling by flow cytometry","volume":"629","author":"Lehmann","year":"2019","journal-title":"Methods Enzymol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.451658","article-title":"Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis","volume":"288","author":"Steelman","year":"2013","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-014-0144-0","article-title":"Astrocyte galectin-9 potentiates microglial TNF secretion","volume":"11","author":"Steelman","year":"2014","journal-title":"J Neuroinflamm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54343","article-title":"The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling","volume":"11","author":"Alame","year":"2021","journal-title":"Theranostics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2024.102426","article-title":"Galectin-9 and Tim-3 are upregulated in response to microglial activation induced by the peptide Amyloid-beta (25-35)","volume":"105","author":"Ramirez Hernandez","year":"2024","journal-title":"Neuropeptides"},{"key":"B18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00401-024-02725-x","article-title":"Stage-dependent immunity orchestrates AQP4 antibody-guided NMOSD pathology: a role for netting neutrophils with resident memory T cells in situ","volume":"147","author":"Nakajima","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1462061","article-title":"The regulating role of galectin-9 in immune cell populations","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: A tale of two central nervous system autoimmune inflammatory disorders","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol Clin"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:33:16Z","timestamp":1791174796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1923404"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1923404","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1923404"}}